Search Results 411-420 of 18369 for alopecia

1. Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer - Mayo Clinic

   Any unresolved toxicity > Common Toxicity Criteria Grade 1 (except alopecia) from previous anticancer therapy (including radiotherapy); History or evidence ...

2. A Study Of Radiation Dosimetry, Safety, And Tolerability Of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment In Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer

   * Participants must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies except alopecia. Key exclusion ...

3. Study to Investigate the Safety and Effectiveness of Two Doses of the Antibody Drug GSK2857916 in Relapsed/Refractory Multiple Myeloma Patients - Mayo Clinic

   ... alopecia and Grade 2 peripheral neuropathy. For France only: A subject will be eligible for inclusion in this study only if either affiliated to or a ...

4. Clinical trials - Oncology (Medical)

   Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...

5. Clinical trials - Oncology (Medical)

   Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...

6. Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer - Mayo Clinic

   *Note: Any adverse events derived from these therapies must be ≤ Grade 2 prior to starting study therapy (exception: alopecia). Participating Mayo Clinic ...

7. Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM) - Mayo Clinic

   - Ongoing Grade 2 or greater toxicities due to previous therapies, excluding alopecia. - Prior external-beam RT resulting in greater than 20% of total bone ...

8. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Vulvar skin disorder, Breast skin change, Rosacea, Pigmentation disorder ...

9. A Dose Escalation Study of HFB301001 in Adult Patients with Advanced Solid Tumors - Mayo Clinic

   - All grades of alopecia are acceptable; - Endocrine dysfunction on replacement therapy is acceptable. - Severe or unstable medical condition, including ...

10. Study to Evaluate Chemoembolization Combined with Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma - Mayo Clinic

    Patients with vitiligo or alopecia; ... Any unresolved toxicity National Cancer Institute (NCI) CTCAE v 5.0 Grade ≥ 2 from previous anticancer therapy, with the ...